Rexahn Pharmaceuticals (RNN) Scheduled to Post Earnings on Monday

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) is scheduled to issue its quarterly earnings data on Monday, February 26th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Shares of Rexahn Pharmaceuticals (NYSEAMERICAN RNN) opened at $1.78 on Monday. Rexahn Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $7.10. The stock has a market cap of $56.46, a PE ratio of -1.91 and a beta of -0.65.

RNN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Friday, November 10th. HC Wainwright reaffirmed a “buy” rating and issued a $19.50 target price on shares of Rexahn Pharmaceuticals in a research report on Monday, November 6th. Finally, ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $13.75.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Earnings History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit